Differences of Tumor Masses and Hemoglobin Levels in Cervical Cancer Squamous Cell Type Patients Treated With Combination of Paclitaxel and Carboplatin Chemotherapy

Noviyani, Rini; Suwiyoga, Ketut; Lesmana, Inge; Niruri, Rasmaya; Tunas, K.; Budiana, And I N. G.

doi:10.15562/bmj.v3i1.63

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Paclitaxel-Carboplatin dinyatakan sebagai obat kemoterapi pada pasien kanker serviks yang sangat direkomendasikan jika dilihat dari efek mengecilnya ukuran tumor, dan memiliki efek samping anemia yang rendah (anemia grade 1). 5 Ifosfamide termasuk dalam kelas agen alkilasi oksazafosforin juga mempunyai aktivitas anti-tumor. Ifosfamide dapat menyebabkan kerusakan sel dengan membentuk ikatan silang interstrand atau intrastrand selanjutnya, menyebabkan apoptosis sel.…”

Section: Pendahuluanunclassified

“…4 Paclitaxel carboplatin menjadi standar obat kemoterapi kanker serviks di RS di Bali karena mampu mengecilkan ukuran tumor, dan memiliki efek samping anemia yang rendah (anemia grade 1). 5 Paclitaxel telah diakui sebagai salah satu agen sitotoksik paling aktif dengan efek samping yang paling umum yang dihasilkan oleh paclitaxel dan carboplatin adalah toksisitas hematologi. 8 Hasil perbandingan dengan kombinasi regimen yang ditambahkan dengan ifosfamide dapat menurunkan volume tumor sebesar 23,66% dan tingkat respon 60%.…”

Section: Pembahasanunclassified

See 1 more Smart Citation

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Danil

Arifuddin²,

Hartono³

et al. 2023

Obgynia

View full text Add to dashboard Cite

Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB. Metode: Sebanyak 30 pasien yang baru terdiagnosis kanker serviks stadium IIB dibagi menjadi dua kelompok terapi kombinasi yaitu kelompok Paclitaxel-Carboplatin-Ifosfamide (TIP) dan Paclitaxel-Carboplatin (TP). Volume tumor dan respon terapi diukur sebelum dan sesudah tiga siklus kemoterapi. Hasil:Tingkat penurunan rata-rata volume tumor pada kelompok Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin sebesar (23,66% vs 39,08%). Tidak ada perbedaan secara bermakna angka respon parsial, angka respon progresif dan tidak ada respon antara kelompok dengan Paclitaxel-Carboplatin-Ifosfamide dengan kelompok Paclitaxel-Carboplatin dengan p > 0,05. Hasil antara Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin pada respon parsial (46,7 % vs 73,3%), respon progresif (13,3% vs 13.3%), dan tidak ada respon (40,0 % vs 1,3%) dan toksisitas kelas 2 lebih dominan pada kelompok Paclitaxel-Carboplatin-Ifosfamide yaitu mual, kerontokan (53,3%) dan fatique, muntah (46,7%). Kesimpulan: Regimen kemoterapi kombinasi Paclitaxel-Carboplatin lebih efektif dalam menurunkan ukuran tumor kanker serviks stadium IIB dengan efek samping yang lebih minimal dibandingkan kombinasi Paclitaxel-Carboplatin-Ifosfamide. Comparison of Therapy Response and Toxicity of Combination Chemotherapy Regimens Between Paclitaxel, Carboplatin And Ifosfamide (PCI) with Paclitaxel and Carboplatin (PC) in Stadium IIB Cervical Cancer Abstract Objective: To compare the therapeutic response and toxicity of a combination chemotherapy regimen of Paclitaxel Carboplatin Ifosfamide with Paclitaxel Carboplatin in stage IIB cervical cancer. Methods: A total of 30 patients newly diagnosed with stage IIB cervical cancer were divided into two combination therapy groups, namely the Paclitaxel-Carboplatin-Ifosfamide (PCI) and Paclitaxel-Carboplatin (PC) groups. Tumor volume and clinical response were measured before and after three cycles. Result: The average reduction rate of tumor volume in the Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin groups was (23.66% vs 39.08%). There was no significant difference in the partial response rate, progressive response rate and no response between the Paclitaxel-Carboplatin-Ifosfamide group and the Paclitaxel-Carboplatin group with p > 0.05. Results between Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin on partial response (46.7% vs 73.3%), progressive response (13.3% vs 13.3%), and no response (40.0% vs 1, 3%) and class 2 toxicity was more dominant in the Paclitaxel-Carboplatin-Ifosfamide group namely nausea, hair loss (53.3%) and fatigue, vomiting (46.7%). Conclusion: The Paclitaxel-Carboplatin combination chemotherapy regimen is more effective in reducing the tumor size of stage IIB cervical cancer with lower side effects than the Paclitaxel-Carboplatin-Ifosfamide combination. Key words: cervical cancer, chemotherapy, side effects

show abstract

Section: Pendahuluanunclassified

Section: Pembahasanunclassified

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Danil

Arifuddin²,

Hartono³

et al. 2023

Obgynia

View full text Add to dashboard Cite

show abstract

“…9 Regimen paklitaksel karboplatin merupakan salah satu regimen kombinasi yang terdapat dalam protap RSUP Sanglah yang memliki efektivitas tinggi namun efek samping yang ditimbulkan tinggi pula. 10 Kemoterapi sangat efektif dalam melawan sel kanker, mengecilkan ukuran tumor, dan memberikan prognosis yang baik pada pasien. 11,12 Pemilihan kemoterapi yang tepat diharapkan mampu meningkatkan kualitas hidup pasien.…”

Section: Pendahuluanunclassified

The Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah

Tunas¹,

Yowani

Indrayathi

et al. 2016

Indones J Clin Pharm

View full text Add to dashboard Cite

Pemberian kemoterapi pada pasien kanker serviks stadium IIB-IIIB selain menimbulkan efek terapi juga menimbulkan efek samping berupa penurunan kualitas hidup. Penelitian ini dilakukan pada Februari-Juni 2014 di Bagian Obstetri dan Gineklogi RSUP Sanglah Denpasar secara observasional dengan metode case study prospective. Pengumpulan data dilakukan menggunakan kuesioner EORTC QLQ C30 yang dikombinasikan dengan wawancara sebelum dan setelah kemoterapi paklitaksel-karboplatin sebanyak 3 seri pada pasien kanker serviks sel skuamosa stadium IIB-IIIB. Penelitian kualitas hidup dilakukan secara umum dan pada 15 domain yang memengaruhi kualitas hidup. Terdapat 12 pasien yang memenuhi kriteria inklusi. Pemberian kemoterapi regimen paklitaksel-karboplatin dapat meningkatkan kualitas hidup dengan penurunan nilai mean dari 48,083±5,451 menjadi 44,083±3,872. Terdapat perbedaan bermakna pada nilai kualitas hidup pasien sebelum dan setelah kemoterapi paklitaksel-karboplatin (nilai p=0,038). Terdapat penurunan kualitas hidup pada domain mual muntah, penurunan nafsu makan, fatigue, dan fungsi sosial. Domain dengan peningkatan kualitas hidup yaitu nyeri, fungsi fisik, fungsi emosional, sulit tidur, dan kesulitan keuangan. Pemberian kemoterapi paklitaksel-karboplatin pada 12 pasien dapat meningkatkan kualitas hidup pasien kanker serviks.

show abstract

Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas

Setijo Rahaju,

Rahniayu,

Hary Kusumastuti

et al. 2024

RJPT

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.

show abstract

Differences of Tumor Masses and Hemoglobin Levels in Cervical Cancer Squamous Cell Type Patients Treated With Combination of Paclitaxel and Carboplatin Chemotherapy

Cited by 3 publications

References 1 publication

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

The Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah

Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas

Contact Info

Product

Resources

About